In particular, Zhongmei Huadong shall be the Marketing Authorization Holder (“MAH”) of QX001S in China to exclusively conduct marketing activities and commercialization of QX001S, who shall make commercially reasonable efforts to promote such commercialization.
Summary · 第 17 页
As of the Latest Practicable Date, we had received the upfront payment and milestone payment in a total of RMB50 million from Zhongmei Huadong under the QX001S Framework Agreement.
Summary · 第 17 页
In order to ensure the successful launch of our first expected commercial drug, QX001S, we formed a strategic collaboration with an established pharmaceutical company, Huadong Medicine, which is experienced in chronic disease management and has strong sales networks for autoimmune and allergic drugs.
We entered into a technology transfer agreement with Joincare Pharmaceutical Group Industry Co., Ltd. (“Joincare”) in January 2024 (the “QX008N Agreement”), to grant Joincare an exclusive license of the know-how and patents controlled by us to develop, manufacture and commercialize QX008N in mainland China, Hong Kong and Macau.
Business · 第 344 页
Pursuant to the QX008N Agreement, Joincare will be responsible for the clinical development (including certain preclinical studies required for BLA approval), regulatory activities, manufacturing and commercialization of QX008N in the licensed territory at its own costs and expenses (other than a part of the Phase Ib clinical trial in China that we have already initiated).
Business · 第 344 页
As of the Latest Practicable Date, we had received the first upfront payment.
国鸿氢能科技（嘉兴）股份有限公司Sino-Synergy Hydrogen Energy Technology (Jiaxing) Co., Ltd.09663.HK
合作开发车型产生的收入占比最高达85.4%
For the years ended 31 December 2020, 2021, 2022 and the five months ended 31 May 2023, revenue generated from the sale of hydrogen fuel cell systems (excluding the additional components of hydrogen storage systems and batteries) for the hydrogen fuel cell vehicle models that we collaborated with the vehicle manufacturers to develop accounted for 48.3%, 78.7%, 64.3% and 85.4% of our total revenue, respectively.
Business · 第 267 页
Revenue from Zhizi Automotive, one of our five largest customers for the year ended 31 December 2022 and the five months ended 31 May 2023, contributed 34.3% and 31.4% of our revenue for the respective year/period, whereas Xiamen King Long, one of our five largest customers for the year ended 31 December 2021, contributed 20.9% of our revenue for the year ended 31 December 2021.
On July 26, 2022 (the “Effective Date”), we entered into an asset transfer agreement (the “CMS Agreement”) with Shenzhen Kangzhe Vision Pharmaceutical Development Co., Ltd. (深圳市康哲維盛醫藥發展有限責任公司) (formerly known as Kangzhe Pharmaceutical Research and Development (Shenzhen) Limited (深圳康哲醫藥發展有限公司)) (“CMS Vision”), a wholly-owned subsidiary of China Medical System Holdings Limited (0867.HK) (together with its subsidiaries, the “CMS Group”), to transfer all of the rights and assets relating to Y400 to CMS Vision.
Summary · 第 23 页
In case of any disagreement that cannot be resolved by negotiations, CMS Vision shall have the final decision-making authority over all matters relating to the development, manufacturing and commercialization of Y400 in the Territory (as defined below).
Summary · 第 23 页
We have received the full upfront payment of US$5 million from CMS Vision.
Innovent will supply the sintilimab injection for free for our use in the combination therapy study.
Summary · 第 19 页
We shall be fully responsible for all the costs and expenses in connection with the conduct of the development activities for the Study and other activities required for the Study except for the cost of sintilimab injection, which Innovent shall provide for free.
Business · 第 317 页
We believe that the CRL issued by the FDA for sintilimab for the first-line treatment of advanced NSCLC will not have a material impact on the Study